After controversy, Plan B sales strong

Like Madonna, the Plan B has faced its share of controversy. Like Hilary Clinton, it's attracted more than its share of political sniping. Like both, it's risen undeterred. Since Plan B was approved for over-the-counter administration last August, sales of the pill have skyrocketed to $80 million for 2007, double the 2006 figure and eight times greater than 2004's. Its manufacturer, Barr Pharmaceuticals, says it's pleased.

Perhaps Barr fears that crowing too loudly about the pill's sales growth will only intensify critics' attempts to overturn the ruling that legalized OTC sales to customers at least 18 years old. A coalition of conservative groups have filed suit against the FDA to do just that. But advocacy groups are just as active, and they want everyone to be able to buy Plan B, regardless of age.

- read the report from The Washington Post

Related Articles:
Barr takes cautious approach in marketing Plan B. Report
FDA clears Plan B, ending FDA confirmation fight. Report
FDA clears way for Plan B to go OTC. Report

Suggested Articles

Pfizer's diagnosis-focused launch strategy for Vyndaqel and Vyndamax is paying off with the meds reaching thousands of patients already.

A phase 1 study of the Inlyta-Keytruda regimen, which bears a first-line nod for kidney cancer, got the ax along with several Bavencio tests.

With its Eli Lilly-partnered Olumiant nearing filing in atopic dermatitis, Incyte's other JAK med Jakafi is also looking for a win in that indication.